Translating Recent Evidence to the Real-World Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Episodes
Specialty:
All
All AI for Oncology Biosimilars Brain Cancer Breast Cancer CAR T-Cell Therapy Disparities in Cancer Care Gastrointestinal Cancer Genitourinary Cancers Global Oncology Graft-vs-Host Disease Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care
EP. 1: Diagnosis and Frontline Management of Diffuse Large B-Cell Lymphoma By Joanna M. Rhodes, MD, MSCE, Jason Westin, MD, MS, FACP, MD Anderson Cancer Center, Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute, Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Yucai Wang, MD, PhD, Mayo Clinic, Hayder M. Saeed, MD, Moffitt Cancer Center Expert panelists open their discussion on diffuse large B-cell lymphoma by reflecting on diagnostic strategies and the frontline treatment armamentarium.
EP. 2: Overview of Relapsed/Refractory DLBCL and Management Strategies By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Joanna M. Rhodes, MD, MSCE, Yucai Wang, MD, PhD, Mayo Clinic, Jason Westin, MD, MS, FACP, MD Anderson Cancer Center, Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute, Hayder M. Saeed, MD, Moffitt Cancer Center Key opinion leaders share a broad perspective on relapsed/refractory diffuse large B-cell lymphoma and the current treatment landscape.
EP. 3: Factors in Selecting Treatment for Relapsed/Refractory DLBCL By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Joanna M. Rhodes, MD, MSCE, Yucai Wang, MD, PhD, Mayo Clinic, Jason Westin, MD, MS, FACP, MD Anderson Cancer Center, Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute, Hayder M. Saeed, MD, Moffitt Cancer Center Focused discussion on specific patient or disease factors that aid in the selection of therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.
EP. 4: Tafasitamab + Lenalidomide Therapy in Relapsed/Refractory DLBCL By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Joanna M. Rhodes, MD, MSCE, Yucai Wang, MD, PhD, Mayo Clinic, Jason Westin, MD, MS, FACP, MD Anderson Cancer Center, Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute, Hayder M. Saeed, MD, Moffitt Cancer Center Panelists review data behind the combination of tafasitamab and lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.
EP. 5: CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Axicabtagene Ciloleucel By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Joanna M. Rhodes, MD, MSCE, Yucai Wang, MD, PhD, Mayo Clinic, Jason Westin, MD, MS, FACP, MD Anderson Cancer Center, Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute, Hayder M. Saeed, MD, Moffitt Cancer Center Shared insight on the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma, with a focus on axicabtagene ciloleucel.
EP. 6: CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Lisocabtagene Maraleucel By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Joanna M. Rhodes, MD, MSCE, Yucai Wang, MD, PhD, Mayo Clinic, Jason Westin, MD, MS, FACP, MD Anderson Cancer Center, Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute, Hayder M. Saeed, MD, Moffitt Cancer Center A brief review of data behind lisocabtagene maraleucel and its role as CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
EP. 7: Real-World Use of CAR T-Cell Therapy in Relapsed/Refractory DLBCL By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Joanna M. Rhodes, MD, MSCE, Yucai Wang, MD, PhD, Mayo Clinic, Jason Westin, MD, MS, FACP, MD Anderson Cancer Center, Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute, Hayder M. Saeed, MD, Moffitt Cancer Center Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
EP. 8: Factors That Inform Sequencing of Therapy in Relapsed/Refractory DLBCL By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Joanna M. Rhodes, MD, MSCE, Yucai Wang, MD, PhD, Mayo Clinic, Jason Westin, MD, MS, FACP, MD Anderson Cancer Center, Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute, Hayder M. Saeed, MD, Moffitt Cancer Center Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
EP. 9: Relapsed/Refractory DLBCL: Managing Patients on CAR T-Cell Therapy By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Joanna M. Rhodes, MD, MSCE, Yucai Wang, MD, PhD, Mayo Clinic, Jason Westin, MD, MS, FACP, MD Anderson Cancer Center, Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute, Hayder M. Saeed, MD, Moffitt Cancer Center A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.
EP. 10: What is the Role of Bispecifics in Relapsed/Refractory DLBCL? By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Joanna M. Rhodes, MD, MSCE, Yucai Wang, MD, PhD, Mayo Clinic, Jason Westin, MD, MS, FACP, MD Anderson Cancer Center, Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute, Hayder M. Saeed, MD, Moffitt Cancer Center Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.
EP. 11: Sequencing Novel Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Joanna M. Rhodes, MD, MSCE, Yucai Wang, MD, PhD, Mayo Clinic, Jason Westin, MD, MS, FACP, MD Anderson Cancer Center, Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute, Hayder M. Saeed, MD, Moffitt Cancer Center Comprehensive insight on the optimal sequencing of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.
EP. 12: Bridging Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Joanna M. Rhodes, MD, MSCE, Yucai Wang, MD, PhD, Mayo Clinic, Jason Westin, MD, MS, FACP, MD Anderson Cancer Center, Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute, Hayder M. Saeed, MD, Moffitt Cancer Center Before closing out their discussion on the relapsed/refractory setting of diffuse large B-cell lymphoma, panelists identify best practices in bridging therapy.
EP. 13: Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Joanna M. Rhodes, MD, MSCE, Yucai Wang, MD, PhD, Mayo Clinic, Jason Westin, MD, The University of Texas MD Anderson Cancer Center, Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute, Hayder M. Saeed, MD, Moffitt Cancer Center Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.
EP. 14: Management of Diffuse Large B-Cell Lymphoma: Data From ASCO 2023 By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Joanna M. Rhodes, MD, MSCE, Yucai Wang, MD, PhD, Mayo Clinic, Jason Westin, MD, MS, FACP, MD Anderson Cancer Center, Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute, Hayder M. Saeed, MD, Moffitt Cancer Center Key opinion leaders reflect on data from the 2023 ASCO meeting and how it may impact the management of diffuse large B-cell lymphoma.
EP. 15: Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Joanna M. Rhodes, MD, MSCE, Yucai Wang, MD, PhD, Mayo Clinic, Jason Westin, MD, MS, FACP, MD Anderson Cancer Center, Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute, Hayder M. Saeed, MD, Moffitt Cancer Center Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.
